SMG
SUPN icon

Spectrum Management Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Spectrum Management Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-15
Closed -$1K – 401
2017
Q3 		$1K Buy
+15
New +$649 ﹤0.01% 346

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Spectrum Management Group's SUPN Position: Q4 2017 in Review

Spectrum Management Group sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 15 shares — an estimated $1K sold.

Spectrum Management Group first reported a position in SUPN in Q3 2017 and held it in 1 quarter. The position peaked at $1K in Q3 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • Spectrum Management Group reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Spectrum Management Group sold 15 Supernus Pharmaceuticals shares in Q4 2017, an estimated $1K.
  • Spectrum Management Group first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Spectrum Management Group's Supernus Pharmaceuticals position peaked at $1K in Q3 2017.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Spectrum Management Group's 13F filing for Q4 2017, filed 7 Feb 2018.